Citizens Financial Group Inc. RI Has $21.12 Million Position in Stryker Corporation $SYK

Citizens Financial Group Inc. RI boosted its stake in shares of Stryker Corporation (NYSE:SYK) by 3.8% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 67,075 shares of the medical technology company’s stock after purchasing an additional 2,464 shares during the quarter. Citizens Financial Group Inc. RI’s holdings in Stryker were worth $21,118,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in SYK. Varma Mutual Pension Insurance Co grew its holdings in Stryker by 10.5% in the 4th quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company’s stock valued at $18,842,000 after buying an additional 5,100 shares during the last quarter. QRG Capital Management Inc. lifted its holdings in shares of Stryker by 7.4% during the fourth quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company’s stock worth $21,281,000 after buying an additional 4,186 shares during the last quarter. Swedbank AB boosted its position in shares of Stryker by 6.6% in the fourth quarter. Swedbank AB now owns 129,027 shares of the medical technology company’s stock valued at $45,349,000 after acquiring an additional 7,934 shares during the period. Crossmark Global Holdings Inc. grew its stake in shares of Stryker by 31.1% in the fourth quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company’s stock worth $9,426,000 after acquiring an additional 6,367 shares during the last quarter. Finally, Royal Bank of Canada grew its stake in shares of Stryker by 6.5% in the first quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock worth $1,075,552,000 after acquiring an additional 199,863 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Down 2.2%

Shares of SYK stock opened at $331.75 on Tuesday. Stryker Corporation has a one year low of $281.00 and a one year high of $396.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The stock has a fifty day moving average price of $325.21 and a 200 day moving average price of $333.24. The stock has a market cap of $127.25 billion, a P/E ratio of 34.38, a price-to-earnings-growth ratio of 2.16 and a beta of 0.76.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. During the same quarter in the previous year, the firm posted $3.13 EPS. The business’s revenue for the quarter was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Analysts predict that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s payout ratio is presently 36.48%.

Analyst Ratings Changes

Several equities analysts recently commented on SYK shares. Evercore set a $350.00 target price on shares of Stryker in a research note on Monday, July 6th. Needham & Company LLC dropped their price objective on shares of Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Citigroup reaffirmed a “buy” rating on shares of Stryker in a research report on Thursday. Citizens Jmp reduced their target price on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a research note on Monday, August 3rd. Finally, Truist Financial lifted their target price on Stryker from $330.00 to $340.00 and gave the stock a “hold” rating in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $386.28.

Insider Activity

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 4.60% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.